Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas

Journal of Neuro-Oncology

Volumn 111, Issue 2, 2013, Pages 187-194

  Minniti, Giuseppe ^a,b   Scaringi, Claudia ^a   De Sanctis, Vitaliana ^a   Lanzetta, Gaetano ^b   Falco, Teresa ^a   Di Stefano, Domenica ^a   Esposito, Vincenzo ^b   Enrici, Riccardo Maurizi ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Glioblastoma; High grade glioma; Recurrence; Reirradiation; Stereotactic radiotherapy; Temozolomide

Indexed keywords

6 FLUORODOPA F 18; DEXAMETHASONE; FOTEMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DIAGNOSTIC AGENT; DOPA; DRUG DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CAUSE OF DEATH; COMPUTED TOMOGRAPHY SCANNER; CONTINUOUS INFUSION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HEADACHE; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN METHYLATION; RADIATION DOSE; RADIATION NECROSIS; RETROSPECTIVE STUDY; SAFETY; SALVAGE THERAPY; SIDE EFFECT; SKIN DISEASE; STEREOTACTIC BODY RADIATION THERAPY; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; SUSCEPTIBILITY WEIGHTED IMAGING; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; BRAIN TUMOR; DISEASE FREE SURVIVAL; METHODOLOGY; MIDDLE AGED; RADIOSURGERY;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DIHYDROXYPHENYLALANINE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; RADIOSURGERY; RETROSPECTIVE STUDIES;

MLCS; MLOWN;

EID: 84879319042     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0999-9     Document Type: Article

References (42)

1. Minniti G, Amelio D, Amichetti M, Salvati M, Muni R, Bozzao A, Lanzetta G, Scarpino S, Arcella A, Enrici RM (2010) Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 97:377-381
2. Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, Biscuola M, Blatt V, Crinò L, Ermani M (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95:1155-1160
3. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, Weller M, Wick W (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357-3361
4. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740
5. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745
6. Kong DS, Lee JI, Kim JH, Kim ST, Kim WS, Suh YL, Dong SM, Nam DH (2010) Phase II rial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol 12:289-296
7. Perry JR, Bélanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28:2051-2057
8. Harsh GR 4th, Levin VA, Gutin PH, Seager M, Silver P, Wilson CB (1987) Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery 21:615-621
9. Dirks P, Bernstein M, Muller PJ, Tucker WS (1993) The value of reoperation for recurrent glioblastoma. Can J Surg 36:271-275
10. Hall WA, Djalilian HR, Sperduto PW, Cho KH, Gerbi BJ, Gibbons JP, Rohr M, Clark HB (1995) Stereotactic radiosurgery for recurrent malignant gliomas. J Clin Oncol 13:1642-1648
11. Shrieve DC, Alexander E III, Wen PY, Fine HA, Kooy HM, Black PM, Loeffler JS (1995) Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 36:275-282
12. Combs SE, Widmer V, Thilmann C, Hof H, Debus J, Schulz-Ertner D (2005) Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer 104:2168-2173
13. Hsieh PC, Chandler JP, Bhangoo S, Panagiotopoulos K, Kalapurakal JA, Marymont MH, Cozzens JW, Levy RM, Salehi S (2005) Adjuvant gamma knife stereotactic radiosurgery at the time of tumor progression potentially improves survival for patients with glioblastoma multiforme. Neurosurgery 57:684-692
14. Patel M, Siddiqui F, Jin JY, Mikkelsen T, Rosenblum M, Movsas B, Ryu S (2009) Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. J Neurooncol 92:185-191
15. Pouratian N, Crowley RW, Sherman JH, Jagannathan J, Sheehan JP (2009) Gamma knife radiosurgery after radiation therapy as an adjunctive treatment for glioblastoma. J Neurooncol 94:409-418
16. Shepherd SF, Laing RW, Cosgrove VP, Warrington AP, Hines F, Ashley SE, Brada M (1997) Hypofractionated radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys 37:393-398
17. Cho KH, Hall WA, Gerbi BJ, Higgins PD, McGuire WA, Clark HB (1999) Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys 45:1133-1141
18. Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term result in 172 patients treated in a single institution. J Clin Oncol 23:8863-8869
19. Vordermark D, Kölbl O, Ruprecht K, Vince GH, Bratengeier K, Flentje M, Vince GH, Bratengeier K (2005) Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer 5:55
20. Ernst-Stecken A, Ganslandt O, Lambrecht U, Sauer R, Grabenbauer G (2007) Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma. J Neurooncol 81:287-294
21. Fokas E, Wacker U, Gross MW, Henzel M, Encheva E, Engenhart-Cabillic R (2009) Hypofractionated stereotactic reirradiation of recurrent glioblastomas: a beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol 185:235-240
22. Henke G, Paulsen F, Steinbach JP, Ganswindt U, Isijanov H, Kortmann RD, Bamberg M, Belka C (2009) Hypofractionated reirradiation for recurrent malignant glioma. Strahlenther Onkol 185:113-119
23. Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, Evans JJ, Hyslop T, Pequignot E, Downes B, Comber E, Maltenfort M, Dicker AP, Werner-Wasik M (2010) Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 28:3048-3053
24. Grosu AL, Weber WA, Franz M, Stärk S, Piert M, Thamm R, Gumprecht H, Schwaiger M, Molls M, Nieder C (2005) Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63:511-519
25. Combs SE, Bischof M, Welzel T, Hof H, Oertel S, Debus J, Schulz-Ertner D (2008) Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. J Neurooncol 89:205-210
26. Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75:156-163
27. Minniti G, Armosini V, Salvati M, Lanzetta G, Caporello P, Mei M, Osti MF, Maurizi RE (2011) Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. J Neurooncol 103:6836-6891
28. Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB, Friedman HS, Willett CG, Kirkpatrick JP (2012) Safety and efficacy of stereotacticradiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 82:2018-2024
29. Niyazi M, Ganswindt U, Schwarz SB, Kreth FW, Tonn JC, Geisler J, la Fougère C, Ertl L, Linn J, Siefert A, Belka C (2012) Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys 82:67-76
30. Park KJ, Kano H, Iyer A, Liu X, Niranjan A, Flickinger JC, Lieberman FS, Lunsford LD, Kondziolka D (2012) Salvage gamma knife stereotactic radiosurgery followedby bevacizumab for recurrent glioblastoma multiforme: a case-control study. J Neurooncol 107:323-333
31. Minniti G, Valeriani M, Clarke E, D'Arienzo M, Ciotti M, Montagnoli R, Saporetti F, Enrici RM (2010) Fractionated stereotactic radiotherapy for skull base tumors: analysis of treatment accuracy using a stereotactic mask fixation system. Radiat Oncol 13(5):1
32. Fowler JF, Tomé WA, Fenwick JD, Mehta MP (2004) A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys 60:1241-1256
33. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963-1972
34. Lederman G, Wronski M, Arbit E, Odaimi M, Wertheim S, Lombardi E, Wrzolek M (2000) Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol 23:155-159
35. Arcicasa M, Roncadin M, Bidoli E, Dedkov A, Gigante M, Trovò MG (1999) Reirradiation and lomustine in patients with relapsed high-grade gliomas. Int J Radiat Oncol Biol Phys 43:789-793
36. Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, Biscuola M, Blatt V, Crinò L, Ermani M (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95(9):1155-1160
37. Brandes AA, Tosoni A, Basso U, Reni M, Valduga F, Monfardini S, Amistà P, Nicolardi L, Sotti G, Ermani M (2004) Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 22:4779-4786
38. Silvani A, Lamperti E, Gaviani P, Eoli M, Fiumani A, Salmaggi A, Falcone C, Filippini G, Botturi A, Boiardi A (2008) Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. J Neurooncol 87:143-151
39. Taal W, Segers-van Rijn JM, Kros JM, van Heuvel I, van der Rijt CC, Bromberg JE, Sillevis Smitt PA, van den Bent MJ (2012) Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study. J Neurooncol 108:195-200
40. van Nifterik KA, van den Berg J, Stalpers LJ, Lafleur MV, Leenstra S, Slotman BJ, Hulsebos TJ, Sminia P (2007) Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. Int J Radiat Oncol Biol Phys 69:1246-1253
41. Chalmers AJ, Ruff EM, Martindale C, Lovegrove N, Short SC (2009) Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent. Int J Radiat Oncol Biol Phys 75:1511-1519
42. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423-436